Research PROSPECT IV (PROStamol: PErspectives of Combination Therapy) in Patients with Benign Prostatic Hyperplasia
DOI:
https://doi.org/10.30841/2307-5090.3.2020.215572Keywords:
benign prostatic hyperplasia, acute urinary retention, Flosin, tamsulosin, Prostamol UnoAbstract
The objective: was to determine the efficacy and safety of nine-year therapy in patients with benign prostatic hyperplasia (ВРН) using the combination «Flosin – Prostamol Uno» by the method of assessing the quality of life and the possibility of improving objective data of urological status. The ultimate goal of nine-year follow-up of patients was to reduce the risk of developing acute urinary retention as a complication of this disease.
Materials and methods. A study of patients with BPH who were included in PROSPECT IV found that 37 people from the entire cohort at the age of 59–78 years (68.2±4.7) remained under observation for 2020 (of n=94 in PROSPECT III – 39.3 % of patients were followed up for 9 years). In a similar way, the subjects were randomized according to the conditions of previous therapy into two groups: the І group (clinical) included 33 patients who received the combination «Flosin – Prostamol Uno» for 9 years; ІІ group (control) consisted of 4 subjects who received a combination «doxazosin – finasteride» also for 9 years.
Results. The obtained results testify to the high therapeutic efficacy of the combination «Flosin – Prostamol Uno», comparable to the combination of drugs «doxazosin and finasteride». Combination therapy with Flosin and Prostamol Uno was well tolerated in patients with a low incidence of adverse events (5.75 %; p <0.05) compared with patients receiving the combination of doxazosin and finasteride (27 %, p <0, 05). 7 (18.9 %) patients were operated on during the last 5 years (TUR – 6; laser vaporization – 1); the level of acute urinary retention – in 7 people in the form of 1–2 episodes, which required operative assistance.
Conclusion. The above facts made it possible to assert that: the adherence of patients to the combined conservative therapy of BPH according to the «Flosin – Prostamol Uno» scheme was high (43.2 %); adherence of patients operated on for acute urinary retention to this type of combination therapy was evident (all patients received Extr. Serenoa repens and tamsulosin in the postoperative period); the level of acute urinary retention in persons of group I with BPH who received treatment for 9 years was 19 % (p> 0.05).References
Аляев Ю.Г., Винаров А.З., Демидко Ю.Л., Спивак Л.Г. (2013) Результаты 10-ти летнего исследования эффективности и безопасности применения экстракта Serenoa repens у пациентов с риском прогрессирования аденомы предстательной железы // Урология. – № 4. – С. 31–35.
Горпинченко И.И., Гурженко Ю.Н. (2011) Исследование ПРОСПЕКТ (ПРОСтамол: ПЕрспективы Комбинированной Терапии) ДГПЖ // Здоровье мужчины. – № 4. – С. 18–20.
Горпинченко И.И., Гурженко Ю.Н., Клименко П.М., Шуляк А.В., Спиридоненко В.В. (2012) Исследование ПРОСПЕКТ II (ПРОСтамол: ПЕрспективы Комбинированной Терапии) при ДГПЖ // Здоровье мужчины. – № 1. – С. 156–160.
Горпинченко И.И., Гурженко Ю.Н., Спиридоненко В.В. (2014) Исследование ПРОСПЕКТ III (ПРОСтамол: ПЕрспективы Комбинированной Терапии) при доброкачественной гиперплазии предстательной железы // Здоровье мужчины. – № 3 (50). – С. 12–17.
Lepor H. (2003) Landmark Studies Impacting the Medical Management of Benign Prostatic Hyperplasia. Rev Urol.; 5(Suppl 4): S34–S41.
Rhodes T., Girman C.J., Jacobsen D.J. et al. (2000) Longitudinal prostate volume in a community-based sample: 7 year follow up in the Olmsted County Study of urinary symptoms and health status among men. J Urol.; 163 (Suppl. 4): 249.
Roehrborn C.G., Boyle P., Bergner D. et al. (1999) Serum prostatespecific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology;54:662–669.
Vinarov A.Z., Spivak L.G., Platonova D.V., Rapoport L.M., Korolev D.O. (2018) 15 years` survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression // Urologia. – С. 1–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Ю. М. Гурженко, В. В. Спиридоненко

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal does not require authors of original (primary) research papers to assign the copyright of their published contributions. Authors grant the journal an non-exclusive licence CC BY 4.0 (Creative Commons Attribution 4.0 International License) to using and the first publication of the original in this journal. Copyright of the manuscripts is retained by the authors, after publication authors retain rights to reuse their papers in their future printed work without first requiring permission from the publisher of the journal and share their own published articles.
The journal supports the self-archiving process. Prior to publication in the journal, authors may post a copy of their manuscript in preparation or submitted to the journal in recognized non-commercial preprint servers, public websites. Authors also are encouraged to archive their final author version of the manuscript in their institution's repositories and, if they wish, on their personal websites. Authors should cite the publication reference and DOI number on the first page of any deposited version, and provide a link from it to the URL of the published article on the journal's website.
To facilitate self-archiving of original research papers and help authors fulfil funder and institutional mandates, the journal deposits manuscripts in National Library of Ukraine by V.I. Vernadsky, Scientific periodicals of Ukraine database and different international scintificd database on behalf of authors who opt-in to this free service during submission. The journal provides depositing of articles on official website of the publisher. The full text access to published papers is free.